Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Immunocytochemical detection of anti-hippocampal antibodies in Alzheimer's disease and normal cerebrospinal fluid.

Loeffler DA, Juneau PL, Nguyen HU, Najman D, Pomara N, LeWitt PA.

Neurochem Res. 1997 Feb;22(2):209-14.

PMID:
9016847
2.

Alzheimer's disease cerebrospinal fluid antibodies display selectivity for microglia. Investigations with cell cultures and human cortical biopsies.

Dahlström A, McRae A, Polinsky R, Nee L, Sadasivan B, Ling EA.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):41-54.

PMID:
7888106
3.

Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease.

Kankaanpää J, Turunen SP, Moilanen V, Hörkkö S, Remes AM.

Neurobiol Dis. 2009 Mar;33(3):467-72. doi: 10.1016/j.nbd.2008.12.001. Epub 2008 Dec 16.

PMID:
19130885
4.

Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies.

McIntyre JA, Chapman J, Shavit E, Hamilton RL, Dekosky ST.

Autoimmunity. 2007 Jul;40(5):390-6.

PMID:
17612901
5.

Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease.

Leuba G, Wernli G, Vernay A, Kraftsik R, Mohajeri MH, Saini KD.

Dement Geriatr Cogn Disord. 2005;19(4):171-83. Epub 2005 Jan 25.

6.

Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown.

Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, Nagele RG.

Brain Res. 2010 Jul 23;1345:221-32. doi: 10.1016/j.brainres.2010.05.038. Epub 2010 Jun 11.

PMID:
20546711
7.

Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease.

McRae A, Dahlström A, Polinsky R, Ling EA.

Behav Brain Res. 1993 Nov 30;57(2):225-34. Review.

PMID:
8117427
8.

Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease.

Costa A, Bini P, Hamze-Sinno M, Moglia A, Franciotta D, Sinforiani E, Ravaglia S, Bole-Feysot C, Hökfelt T, Déchelotte P, Fetissov SO.

J Neuroimmunol. 2011 Dec 15;240-241:114-20. doi: 10.1016/j.jneuroim.2011.10.003. Epub 2011 Nov 10.

PMID:
22078238
9.

Microglial cerebrospinal fluid antibodies. Significance for Alzheimer disease.

McRae A, Ling EA, Wigander A, Dahlström A.

Mol Chem Neuropathol. 1996 May-Aug;28(1-3):89-95.

PMID:
8871946
10.

Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease.

Ikonomovic MD, Mizukami K, Warde D, Sheffield R, Hamilton R, Wenthold RJ, Armstrong DM.

Exp Neurol. 1999 Nov;160(1):194-204.

PMID:
10630204
11.
12.

Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease.

Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N, Tsolaki M, Chatzopoulos D, Katsinelos P, Tzilves D, Zabouri A, Michailidou I.

Int J Neurosci. 2009;119(6):765-77. doi: 10.1080/00207450902782083.

PMID:
19326283
13.

Neuronal RNA in relation to Alz-50 immunoreactivity in Alzheimer's disease.

Doebler JA, Markesbery WR, Anthony A, Davies P, Scheff SW, Rhoads RE.

Ann Neurol. 1988 Jan;23(1):20-4.

PMID:
2449843
14.

Immunoreactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons.

Attems J, Quass M, Gartner W, Nabokikh A, Wagner L, Steurer S, Arbes S, Lintner F, Jellinger K.

Exp Gerontol. 2007 Mar;42(3):215-22. Epub 2006 Nov 20.

PMID:
17116382
15.

Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Mizukami K, Akatsu H, Abrahamson EE, Mi Z, Ikonomovic MD.

Neuropathology. 2016 Apr;36(2):135-45. doi: 10.1111/neup.12241. Epub 2015 Aug 21.

16.

Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis.

Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ.

Ann Neurol. 2014 Jul;76(1):108-19. doi: 10.1002/ana.24195. Epub 2014 Jun 27.

17.

An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease.

Mizukami K, Ishikawa M, Akatsu H, Abrahamson EE, Ikonomovic MD, Asada T.

Neuropathology. 2011 Oct;31(5):503-9. doi: 10.1111/j.1440-1789.2010.01193.x. Epub 2011 Jan 27.

18.

Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target.

Borroni B, Stanic J, Verpelli C, Mellone M, Bonomi E, Alberici A, Bernasconi P, Culotta L, Zianni E, Archetti S, Manes M, Gazzina S, Ghidoni R, Benussi L, Stuani C, Di Luca M, Sala C, Buratti E, Padovani A, Gardoni F.

Sci Rep. 2017 Jul 27;7(1):6723. doi: 10.1038/s41598-017-06117-y. Erratum in: Sci Rep. 2018 Jan 5;8(1):272.

19.
20.

Changes in hippocampal GABABR1 subunit expression in Alzheimer's patients: association with Braak staging.

Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Hidaka S, Abrahamson EE, DeKosky ST, Asada T.

Acta Neuropathol. 2005 May;109(5):467-74. Epub 2005 Mar 10.

PMID:
15759131

Supplemental Content

Support Center